selected scholarly activity
-
chapters
- Ask your doctor direct-to-consumer advertising of prescription medicines. 362-377. 2014
- At any price? paying for new cancer drugs. 280-311. 2014
- Long-term care reform in Ontario “the long delivery”. 419-441. 2014
- The cost and cost-effectiveness of lung cancer management. 247-263. 2008
-
conferences
- GROUP ACUPUNCTURE IS MORE COST-EFFECTIVE THAN INDIVIDUAL ACUPUNCTURE FOR TREATING CANCER-RELATED PAIN. Annals of Behavioral Medicine. S243-S243. 2021
- A systematic review of non-interventional studies reporting on humanistic and economic burden of cognitive decline in multiple sclerosis patients regardless of study design. European Journal of Neurology. 533-533. 2018
- An Analysis of Mental Health Program Funding for Child and Youth in the Canadian Yukon Territory. Journal of Mental Health Policy and Economics. S27-S27. 2015
- Competency Development to Meet Rural and Remote Mental Health Needs: A Case Study of Child and Youth Mental Health Policy in Yukon, Canada. Journal of Mental Health Policy and Economics. S29-S30. 2015
- Effectiveness of Health System Services and Programs for Youth to Adult Transitions in Mental Health Care: A Systematic Review of Academic Literature. Journal of Mental Health Policy and Economics. S12-S13. 2015
- CAREGIVER SELF-ADMINISTERED FINANCIAL EXPENDITURES (C-SAFE) FOR PEDIATRIC CANCER: ADAPTING AN ESTABLISHED INSTRUMENT. Pediatric Blood and Cancer. S363-S363. 2014
- Myth or Reality: Are Head and Neck Cancer Patients at Increased Risk for Suicidal Thoughts and Gestures? Preliminary Results. Psycho-Oncology. 206-207. 2013
- Myth or reality: are head and neck cancer patients at increased risk for suicidal thoughts and gestures?: Preliminary results. Quality of Life Research. 2013
- PDB35 COST-CONSEQUENCE ANALYSIS OF CSII VS. MDI:A CANADIAN PERSPECTIVE. Value in Health. A290-A290. 2010
- PCN143 COST-EFFECTIVENESS OBSERVATIONS AND ONCOLOGY DRUG REIMBURSEMENT RECOMMENDATIONS IN CANADA BY THE JOINT ONCOLOGY DRUG REVIEW. Value in Health. A51-A51. 2010
- Economic guidelines for oncology products: Adaptation of the Canadian Agency for Drugs and Technologies in Health (CADTH) technology assessment guidance document. Journal of Clinical Oncology. 2009
- A LONG TERM FOLLOW-UP STUDY INVESTIGATING HEALTH RELATED QUALITY OF LIFE AND RESOURCE USE IN SURVIVORS OF SEVERE SEPSIS: COMPARISON OF RECOMBINANT HUMAN ACTIVATED PROTEIN C TO STANDARD CARE.. Critical Care Medicine. A110-A110. 2006
- Characteristics of out-of-pocket costs for cancer patients in Ontario, Canada. Journal of Clinical Oncology. 791S-791S. 2004
- P.1.190 Prevalence and management of depression with painful physical symptoms in a Canadian claims database. European Neuropsychopharmacology. S255-S256. 2003
-
journal articles
- SIOG2024-4-P-094 Impact of income on physical/emotional concerns and helpseeking by adult survivors of cancer (65+ years). Journal of Geriatric Oncology. 15:101975. 2024
- Patient and Family Financial Burden in Cancer: A Focus on Differences across Four Provinces, and Reduced Spending Including Decisions to Forego Care in Canada. Current Oncology. 31:2713-2726. 2024
- The cost and value of cancer medicines in Ontario, Canada. The Lancet Oncology. 25:412-413. 2024
- Impact of Income on Physical Concerns, Help Seeking, and Unmet Needs of Adult Cancer Survivors. Physiotherapy Canada. Physiotherapie Canada. 75:339-347. 2023
- The association of cancer-related fatigue on the social, vocational and healthcare-related dimensions of cancer survivorship. Journal of Cancer Survivorship. 2023
- Relationship between income and concerns about physical changes and help-seeking by older adult cancer survivors: a secondary analysis. BMC Geriatrics. 23:184. 2023
- Societal Perspectives and Real-World Cost-Effectiveness: Expanding the Scope of Health Economics Inquiry. Current Oncology. 30:233-235. 2022
- Longitudinal Assessment of Labor Market Earnings Among Patients Diagnosed With Cancer in Canada. JAMA network open. 5:e2245717-e2245717. 2022
- Clinical Management of Financial Toxicity–Identifying Opportunities through Experiential Insights of Cancer Survivors, Caregivers, and Social Workers. Current Oncology. 29:7705-7717. 2022
-
Out‐of‐pocket costs associated with head and neck cancer treatment. Cancer Reports. 5:e1528. 2022 - Relationships between Canadian adult cancer survivors’ annual household income and emotional/practical concerns, help‐seeking and unmet needs. Health and Social Care in the Community. 30:e1290-e1301. 2022
- Linking Intermediate to Final “Real-World” Outcomes: Is Financial Toxicity a Reliable Predictor of Poorer Outcomes in Cancer?. Current Oncology. 29:2483-2489. 2022
- Experiencing financial toxicity associated with cancer in publicly funded healthcare systems: a systematic review of qualitative studies. Journal of Cancer Survivorship. 16:314-328. 2022
- Exploring the relationships between income and emotional/practical concerns and help-seeking by older adult cancer survivors: A secondary analysis. Journal of Geriatric Oncology. 13:337-345. 2022
- Is vaccine hesitancy justified? Benchmarking post-market vaccine risks with five commonly used medicinal products in Canada. Canadian Journal of Public Health. 113:196-203. 2022
- Pragmatic pharmacoeconomic analyses by using post-market adverse drug reaction reports: an illustration using infliximab, adalimumab, and the Canada vigilance adverse reaction database. BMC Health Services Research. 21:1231. 2021
- Unequal distribution of financial toxicity among people with cancer and its impact on access to care: a rapid review. Current opinion in supportive and palliative care. 15:157-161. 2021
- Emerging Understanding About the Impact of Financial Toxicity Related to Cancer: Canadian Perspectives. Seminars in Oncology Nursing. 37:151174-151174. 2021
- Unrecognized assets created by public-sector investments in health and social services. Journal of Public Budgeting, Accounting and Financial Management. 33:409-426. 2021
- Correction to: Patient and family financial burden associated with cancer treatment in Canada: a national study. Supportive Care in Cancer. 29:3387-3388. 2021
- Patient and family financial burden associated with cancer treatment in Canada: a national study. Supportive Care in Cancer. 29:3377-3386. 2021
- Cost–Utility of Group Versus Individual Acupuncture for Cancer-Related Pain Using Quality-Adjusted Life Years in a Noninferiority Trial. Journal of Alternative and Complementary Medicine. 27:390-397. 2021
- Cancer patients’ perspectives on financial burden in a universal healthcare system: Analysis of qualitative data from participants from 20 provincial cancer centers in Canada. Patient Education and Counseling. 104:903-910. 2021
- Financial toxicity associated with a cancer diagnosis in publicly funded healthcare countries: a systematic review. Supportive Care in Cancer. 28:4645-4665. 2020
- Translation and Cultural Adaptation of the Patient Self-Administered Financial Effects (P-SAFE) Questionnaire to Assess the Financial Burden of Cancer in French-Speaking Patients. Healthcare (Switzerland). 8:366-366. 2020
- When are Pharmaceuticals Priced Fairly? An Alternative Risk-Sharing Model for Pharmaceutical Pricing. Health Care Analysis : HCA. 28:121-136. 2020
- Adverse Drug Reactions in Canada in 2009–2018: Insights from the Canada Vigilance Database. Healthcare Quarterly. 23:40-46. 2020
- The 2018 decision to establish an Advisory Council on adding pharmaceuticals to universal health coverage in Canada. Health Policy. 124:7-11. 2020
- Elective Repeat Caesarean Section in Low-Risk Women—Economic Evaluation Comparing Births Before vs. After 39 Weeks Gestation in Ontario, Canada. Journal of Obstetrics and Gynaecology Canada. 40:1600-1607. 2018
- Exploring the impact of out-of-pocket costs on the quality of life of Canadian cancer patients. Journal of Psychosocial Oncology. 36:582-596. 2018
- The Economic Burden of Bladder Cancer Due to Occupational Exposure. Journal of Occupational and Environmental Medicine. 60:217-225. 2018
- Feasibility of Assessing Patient Health Benefits and Incurred Costs Resulting from Early Dysphagia Intervention during and Immediately after Chemoradiotherapy for Head-and-Neck Cancer. Current Oncology. 24:466-476. 2017
- Design of effective interventions for smoking cessation through financial and non-financial incentives. Healthcare Management Forum. 30:289-292. 2017
- The transition from youth to adult mental health services and the economic impact on youth and their families. Healthcare Management Forum. 30:283-288. 2017
- Differences in growth of Canadian children compared to the WHO 2006 Child Growth Standards. Paediatric and Perinatal Epidemiology. 31:452-462. 2017
- Public Health Policy in Support of Insurance Coverage for Smoking Cessation Treatment. Healthcare Policy. 12:56-68. 2017
- A Tale of Two Health-Care Systems: Cost-Utility Analysis of Open Carpal Tunnel Release in Canada and the United States. Plastic Surgery. 25:7-13. 2017
- Understanding the full breadth of cancer-related patient costs in Ontario: a qualitative exploration. Supportive Care in Cancer. 24:4541-4548. 2016
- A scoping review of evaluated interventions addressing developmental transitions for youth with mental health disorders. Child: Care, Health and Development. 42:176-187. 2016
- Effectiveness of Health System Services and Programs for Youth to Adult Transitions in Mental Health Care: A Systematic Review of Academic Literature. Administration and Policy in Mental Health and Mental Health Services Research. 43:259-269. 2016
- Comparative Effectiveness of Phosphate Binders in Patients with Chronic Kidney Disease: A Systematic Review and Network Meta-Analysis. PLoS ONE. 11:e0156891-e0156891. 2016
- Do National Frameworks Help in Local Policy Development? Lessons from Yukon about the Evergreen Child and Youth Mental Health Framework. Canadian Journal of Community Mental Health. 34:111-128. 2015
- Risk of adverse outcomes among infants of immigrant women according to birth-weight curves tailored to maternal world region of origin. CANADIAN MEDICAL ASSOCIATION JOURNAL. 187:E32-E40. 2015
- Cost-sharing for health care services: An alternative strategy for pharmaceutical reimbursement in ontario. Journal of Population Therapeutics and Clinical Pharmacology. 22:e245-e250. 2015
- How do business model and health technology design influence each other? Insights from a longitudinal case study of three academic spin-offs. Research Policy. 43:1025-1038. 2014
- Building Business Relationships Through the Web: How Medical Technology Companies Enroll Stakeholders in Innovation Development and Uptake. International Review of Social Research. 3:89-112. 2013
- Do Canadian Researchers and the Lay Public Prioritize Biomedical Research Outcomes Equally? A Choice Experiment. Academic Medicine. 88:519-526. 2013
- Guidelines for Health Technologies: Specific Guidance for Oncology Products in Canada. Value in Health. 15:580-585. 2012
- The value of fixed reimbursement insurance against cancer related losses: simulations to investigate state dependent utility. Global Business and Economics Review. 14:322-322. 2012
- Encouraging pharmaceutical innovation to meet the needs of both developed and developing countries. International Journal of Development Issues. 10:92-101. 2011
- Cost-Effectiveness of Transdermal Nitroglycerin Use for Preterm Labor. Value in Health. 14:240-246. 2011
- A Comparative Analysis of Monthly Out-of-Pocket Costs for Patients with Breast Cancer as Compared with Other Common Cancers in Ontario, Canada. Current Oncology. 18:681-681. 2011
- Equitable Access to Healthcare Services and Income Replacement for Cancer: Is Critical Illness Insurance a Help or a Hindrance?. Healthcare Policy. 5:e113-e119. 2010
- Estimating the National Wage Loss from Cancer in Canada. Current Oncology. 17:40-49. 2010
- Global pharmaceutical pricing strategies: profit implications of price discounting. Int. J. of Economics and Business Research. 2:447-460. 2010
- Economic guidelines for oncology products: Adaptation of the Canadian Agency for Drugs and Technologies in Health (CADTH) technology assessment guidance document. Journal of Clinical Oncology. 27:e17572-e17572. 2009
- A prospective, observational registry of patients with severe sepsis: The Canadian Sepsis Treatment and Response Registry*. Critical Care Medicine. 37:81-88. 2009
- Barriers to healthy behaviours for people with type 2 diabetes: what role do patient out-of-pocket costs play?. Canadian Journal of Diabetes. 33:259-259. 2009
- Universal or Targeted Screening for Fetal Alcohol Exposure: A Cost-Effectiveness Analysis. Journal of Studies on Alcohol and Drugs. 69:510-519. 2008
- A long-term follow-up study investigating health-related quality of life and resource use in survivors of severe sepsis: comparison of recombinant human activated protein C with standard care. Critical Care. 12:429-429. 2008
- An examination of cancer patients’ monthly ‘out-of-pocket’ costs in Ontario, Canada. European Journal of Cancer Care. 16:500-507. 2007
- A long-term follow-up study investigating health-related quality of life and resource use in survivors of severe sepsis: comparison of recombinant human activated protein C with standard care. Critical Care. 11:R128-R128. 2007
- Financial and family burden associated with cancer treatment in Ontario, Canada. Supportive Care in Cancer. 14:1077-1085. 2006
- THE CANADIAN SEPSIS TREATMENT AND RESPONSE (STAR) REGISTRY: ILLNESS SEVERITY AND PROCESS OF CARE FOR PATIENTS WITH SEVERE SEPSIS. Critical Care Medicine. 32:A149-A149. 2004
- Characteristics of out-of-pocket costs for cancer patients in Ontario, Canada. Journal of Clinical Oncology. 22:8251-8251. 2004
- Characteristics of out-of-pocket costs for cancer patients in Ontario, Canada. Journal of Clinical Oncology. 22:8251-8251. 2004
- Economic benefits of pioglitazone for treating patients with Type 2 diabetes. Expert Review of Pharmacoeconomics and Outcomes Research. 4:135-142. 2004
- Patient characteristics and costs of severe sepsis and septic shock in Quebec. Journal of Critical Care. 17:39-49. 2002
- The Economic Value of a New Insulin Preparation, Humalog?? Mix 25???. PharmacoEconomics (Auckland). 18:275-287. 2000
- Choices of Methodology in Pharmacoeconomic Studies. Medical Care. 37:AS32-AS35. 1999
- Pictorial Essay. MRI of the Glenoid Labrum with Gross Anatomic Correlation. Journal of Computer Assisted Tomography. 20:487-495. 1996
- Hepatic extraction of insulin after stimulation of secretion with oral glucose or parenteral nutrients. Metabolism: Clinical and Experimental. 42:921-927. 1993
- How to Inform Vaccine Hesitant Individuals about the Potential Risks Associated with Vaccination. McMaster University Journal of Public Health. 1.
- Putting National Pharmacare on the Federal Agenda: Creation of an Advisory Council. Health Reform Observer - Observatoire des Réformes de Santé. 7.
-
other
-
scholarly editions